# Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

> **NCT04635995** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Lyvgen Biopharma Holdings Limited** · enrollment: 126 (estimated)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** LVGN7409

## Key facts

- **NCT ID:** NCT04635995
- **Lead sponsor:** Lyvgen Biopharma Holdings Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-11
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04635995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04635995, "Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04635995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*